Dusquetide for the Treatment of Behcet's Disease
Trial details
- Registry ID
- NCT06386744
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as SGX942; SGX945
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Dusquetide for the Treatment of Behcet's DiseaseNCT06386744 | Soligenix | Phase 2 | Completed | 2025-05-23Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |